Certara, Inc. (NASDAQ:CERT) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 13.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,557,951 shares of the company's stock after purchasing an additional 557,348 shares during the quarter. Teacher Retirement System of Texas owned about 2.83% of Certara worth $48,542,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Thrivent Financial for Lutherans grew its holdings in Certara by 128.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 196,391 shares of the company's stock valued at $2,091,000 after buying an additional 110,481 shares in the last quarter. Nicholas Company Inc. lifted its position in Certara by 47.9% during the fourth quarter. Nicholas Company Inc. now owns 558,888 shares of the company's stock valued at $5,952,000 after purchasing an additional 181,008 shares during the last quarter. ANTIPODES PARTNERS Ltd grew its position in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after acquiring an additional 3,656 shares in the last quarter. HighTower Advisors LLC lifted its stake in shares of Certara by 647.2% in the 4th quarter. HighTower Advisors LLC now owns 146,539 shares of the company's stock valued at $1,561,000 after purchasing an additional 126,927 shares during the last quarter. Finally, Amundi raised its holdings in Certara by 222.8% during the 4th quarter. Amundi now owns 62,167 shares of the company's stock valued at $685,000 after buying an additional 42,907 shares during the period. Institutional investors own 73.96% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have weighed in on CERT shares. Barclays boosted their price objective on shares of Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. William Blair reiterated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 price target for the company. Finally, Stephens reiterated an "overweight" rating and issued a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Certara presently has an average rating of "Moderate Buy" and a consensus price target of $15.83.

Certara Stock Down 4.3 %

Shares of NASDAQ:CERT traded down $0.46 during trading hours on Tuesday, hitting $10.32. The company's stock had a trading volume of 920,318 shares, compared to its average volume of 1,012,197. The firm's fifty day moving average price is $12.54 and its 200 day moving average price is $11.48. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.18. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -51.60, a P/E/G ratio of 9.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.